Primary Colour:
Primary Text:
Secondary Colour:
Secondary Text:
Tertiary Colour:
Tertiary Text:
Colour Picker
Preview
FeaturesTypographyTutorials
Module Title
Home
Module Title

This block of text is used as an example for the colour chooser module on this web site. This paragraph is functionally unimportant, and can safely be ignored.

Module Title
Module Title
Instructions

Select a predefined style from the drop-down or choose your own colours via the handy colour-chooser. When you are satisfied with your selection, click the "Apply Colours" button below to store your selection in a cookie.

Apply Colours

Holyrood opinion poll

With the publication of the interim Calman Report, do you think –
 
Home
Settlement agreed in NHS drugs case Print E-mail
Tuesday, 04 March 2008

Scottish ministers and health boards have reached settlement with a major international pharmaceutical company on alleged anti-competitive cartel conduct in connection with the supply of drugs to the NHS. 

Goldshield Group, Goldshield Pharmaceuticals and Forley Generics have agreed, without admitting liability, to pay £750,000 in compensation and to provide co-operation in connection with continuing civil claims against a number of other companies regarding alleged price fixing arrangements for a number of generic drugs.

Cabinet Secretary for Health and Wellbeing Nicola Sturgeon said: "I am delighted that we have managed to reach a settlement agreement with Goldshield. This is a satisfactory conclusion to our negotiations." 

Goldshield Group chairman Keith Hellawell said: "We recognise the importance of building strong working relationships with our customers. We view the NHS as a valued customer and are therefore very pleased with today's settlement."

In February 2005, Scottish ministers and health boards lodged claims in the civil courts in England against a number of companies, in connection with forming alleged price-fixing cartels involving Warfarin, Ranitidine and Penicillin-based drugs. 

Goldshield Group, Goldshield Pharmaceuticals and Forley Generics have already settled a similar claim with the Department of Health in England.
No one has commented on this article.
The author or administrator has closed this item for comments.


Related news items:
 
[ Back ]

Featured sites

Site news...


Have your say: We have introduced a comments system in our news and magazine article sections, submit your comments for approval. Your comments  will feature in the "Your comments" section.
 
Visitors: 6513304
We have 19 guests online